Completed
These studies have finished collecting, analyzing, and reporting data and are now archived.
-
CTN 203: Phase I/II study of Remune® plus Amplivax™
A Phase I/II safety and immunogencity study of a combination of whole-killed HIV-1 antigen and Amplivax, administered with or without IFA, in HIV-1 infected Participants: Trial results
-
CTN 190: Strategies for management of ART (The SMART Study)
A Comparison of Two Ways to Manage Anti-HIV Treatment
-
CTN 173: Vaccination before treatment interruption
A pilot study to determine the impact of therapeutic HIV vaccination followed by a scheduled interruption of antiretroviral therapy on HIV-specific immune function and virologic rebound in patients with prolonged viral suppression: Trial results
-
CTN 167: Options with antiretrovirals (OPTIMA)
A tri-national (Canada, UK, USA) randomized, controlled trial to determine the optimal management of patients with HIV infection for whom first and second-line highly active antiretroviral therapy has failed
-
CTN 164: Treatment Interruption
A Prospective Randomized Trial of Structured Treatment Interruption (STI) Followed by the Initiation of a New Antiretroviral Regimen vs. Immediate Switching to a New Antiretroviral Regimen in HIV-Infected Patients Experiencing Virologic Failure on HAART
-
CTN 161: Simplified Protease Inhibitor Trial (SPRINT)
An International, Open-Label, Randomized, Multicentre Study to Evaluate the Antiviral Effect, Tolerability, Safety and Pharmacokinetics of Fortovase (saquinavir SGC) and Norvir (ritonavir) QD vs. Crixivan (indinavir) and Norvir (ritonavir) BID in HIV-Infected Patients
-
CTN 160: The Double Non-Nucleoside Study (2NN Study)
An Open-Label, Comparative Study to Evaluate the Antiviral Efficacy and Safety of Nevirapine and Efavirenz or Both Drugs Combined in Combination with d4T and 3TC. (The 2NN or Double Non-Nucleoside Study): Trial results
-
CTN 158: The CpG ODN 7909 as an Adjuvant and Immune Modulator
Phase I Safety and Immunogenicity Study of CpG ODN 7909 as an Immune Modulator and Adjuvant to Engerix®-B Vaccine in Haart-Treated, HIV-Positive Patients: Trial results
-
CTN 151: Multiple Drug Rescue Therapy
A Pilot Study Comparing Two Modalities of Multiple Drug Rescue Therapy (MDRT) among Pre-Treated, HIV-1 Infected Individuals – Full versus Sensitivity-Based MDRT Protocol: Trial results
-
CTN 149: Two PIs versus Efavirenz, with Two NRTIs
Open-Label, Randomized, Multicenter Study to Evaluate Fortovase® (Saquinavir SGC) QD, Norvir® (Ritonavir) QD plus Two NRTIs Vs. SustivaTM (Efavirenz) QD plus Two NRTIs in HIV-Infected Patients: Trial results
-
CTN 147: Early versus delayed pneumococcal vaccination
A pilot study assessing the efficacy of pneumococcal vaccine in HIV patients: delayed versus immediate immunization: Trial results
-
CTN 145: rIL-2 to slow progression of HIV (SILCAAT)
A Phase III, multicentre, randomized study of the biological and clinical efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with low CD4+ counts under active antiretroviral therapy(SILCAAT): Trial results
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.v
Learn More